FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1062-1064 September 7, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Talpaz, M. PubMed Citation

To the Editor: According to the findings of Talpaz et al. (June 15 issue),¹ the efficacy and safety profile of dasatinib therapy in patients with Philadelphia chromosome–positive leukemias and resistance to or intolerance of imatinib seem promising. Nevertheless, pleural effusions developed in about 20% of the patients. The authors do not mention how many patients had to undergo thoracentesis or pleurodesis, or whether this complication was dose-dependent.

Satheesh K. Kathula, M.D.
Wright State University
Dayton, OH 45409
kathulask@yahoo.com

1. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541. [Free Full Text]

This article has been cited by other articles:

• Lee, T.-S., Ma, W., Zhang, X., Giles, F., Cortes, J., Kantarjian, H., Albitar, M. (2008). BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Molecular Cancer Therapeutics 7: 3834-3841 [Abstract] [Full Text]